Repositioning Candidate Details
| Candidate ID: | R0365 |
| Source ID: | DB01238 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Aripiprazole |
| Synonyms: | |
| Molecular Formula: | C23H27Cl2N3O2 |
| SMILES: | ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl |
| Structure: |
|
| DrugBank Description: | Aripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's[Label]. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania[Label]. Aripiprazole exerts its effects through agonism of dopaminic and 5-HT1A receptors and antagonism of alpha adrenergic and 5-HT2A receptors[Label,A4393]. Aripiprazole was given FDA approval on November 15, 2002[L6136]. |
| CAS Number: | 129722-12-9 |
| Molecular Weight: | 448.385 |
| DrugBank Indication: | Aripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label]. |
| DrugBank Pharmacology: | Aripiprazole has high affinity for serotonin type 2 (5HT2), dopamine type 2 (D2), alpha1 and 2 adrenergic, and H1 histaminergic receptors[Label,A4393]. It also acts on a number of other receptors with lower affinity[Label,A4393]. The exact method by which aripiprazole's action on these receptors translates to a clinically relevant effect is not yet known[Label]. |
| DrugBank MoA: | The antipsychotic action of aripiprazole is likely due to the agonism of D2 and 5-HT1A receptors though the exact mechanism has not been defined[Label,A4393]. Some adverse effects may be due to action on other receptors[Label]. For example, orthostatic hypotension may be explained by antagonism of the adrenergic alpha1 receptors[Label,A4393]. |
| Targets: | Dopamine D2 receptor; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 1A; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Dopamine D3 receptor; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 7; Alpha-2A adrenergic receptor; Alpha-2C adrenergic receptor; Histamine H1 receptor; 5-hydroxytryptamine receptor 1B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 6; Dopamine D1 receptor; Dopamine D4 receptor; Alpha-2B adrenergic receptor; 5-hydroxytryptamine receptor 1E; Dopamine D5 receptor; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 5A; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Histamine H2 receptor; Histamine H3 receptor; Histamine H4 receptor; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M4; Muscarinic acetylcholine receptor M5; Kappa-type opioid receptor; Mu-type opioid receptor; Delta-type opioid receptor; Glutamate (NMDA) receptor; Sodium-dependent dopamine transporter; Sodium-dependent serotonin transporter |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|